Search Results - "Krajsova, I"

More than 5000 patients with metastatic melanoma in Europe per year do not have access to recommended first-line innovative treatments by Kandolf Sekulovic, L, Peris, K, Hauschild, A, Stratigos, A, Grob, J.-J, Nathan, P, Dummer, R, Forsea, A.-M, Hoeller, C, Gogas, H, Demidov, L, Lebbe, C, Blank, C, Olah, J, Bastholt, L, Herceg, D, Neyns, B, Vieira, R, Hansson, J, Rutkowski, P, Krajsova, I, Bylaite-Bucinskiene, M, Zalaudek, I, Maric-Brozic, J, Babovic, N, Banjin, M, Putnik, K, Weinlich, G, Todorovic, V, Kirov, K, Ocvirk, J, Zhukavets, A, Kukushkina, M, De La Cruz Merino, L, Ymeri, A, Risteski, M, Garbe, C

“…Abstract Background Despite the efficacy of innovative treatments for metastatic melanoma, their high costs has led to disparities in cancer care among…”
Get full text

ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, M.O., Robert, C., Negrier, S., In, G.K., Walker, J., Krajsova, I., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Shaw, H.M., Cheng, T., Mansard, S., Grob, J.J., Guidoboni, M., Mehta, M., Ascierto, P.A., Diab, A.

Get full text

3301 Two year estimate of overall survival in COMBI-v, a randomized, open-label, phase III study comparing the combination of dabrafenib (D) and trametinib (T) with vemurafenib (Vem) as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma by Robert, C, Karaszewska, B, Schachter, J, Rutkowski, P, Mackiewicz, A, Stroyakovskiy, D, Lichinitser, M, Dummer, R, Grange, F, Mortier, L, Chiarion-Sileni, V, Drucis, K, Krajsova, I, Hauschild, A, Mookerjee, B, Legos, J, Schadendorf, D

Get full text

1113P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (enco) + binimetinib (bini) vs vemurafenib (vemu) or enco in patients (pts) with BRAF V600–mutant melanoma by Schadendorf, D., Dummer, R., Flaherty, K.T., Robert, C., Arance Fernandez, A.M., de Groot, J.W., Garbe, C., Gogas, H., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Guenzel, C.A., Polli, A., Thakur, M., di Pietro, A., Ascierto, P.A.

Get full text

786O Tumor biomarker analysis from COLUMBUS part 1: Encorafenib + binimetinib for BRAF V600E/K-mutant advanced or metastatic melanoma by Dummer, R., Pathan, N., Deng, S., Robert, C., Arance Fernandez, A.M., de Groot, J.W.B., Garbe, C., Gogas, H.J., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandala, M., Schadendorf, D., Yamazaki, N., di Pietro, A., Xie, T., Ascierto, P.A., Flaherty, K.

Get full text

An Update on Access to Novel Treatment for Metastatic Melanoma in Europe — A 2024 Survey of the European Melanoma Registry and the European Association of Dermato-Oncology by Kandolf, L, Ascierto, P, Bastholt, L, Gavrilova, I, Haanen, J, Hauschild, A, Herceg, D, Hoeller, C, Jalovcic Suljevic, A, Kessels, JI, Krajsova, I, Kukushkina, M, Lallas, A, Lorigan, P, Mangana, J, Marquez-Rodas, I, Mazilu, L, Mohr, P, Bylaite-Bucinskiene, M, Ocvirk, J, Olah, J, Putnik, K, Rutkowski, P, Saiag, P, Samolyenko, I, Schwarze, JK, Stojkovski, I, Cicmil Sarić, N, Vieira, R, Weichenthal, M, Garbe, C

Get full text

602P COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma by Haydon, A.M., Schadendorf, D., Dummer, R., Flaherty, K.T., Robert, C., Arance Fernandez, A.M., de Groot, J.W., Garbe, C., Gogas, H., Gutzmer, R., Krajsova, I., Liszkay, G., Loquai, C., Mandalà, M., Yamazaki, N., Guenzel, C.A., Polli, A., Thakur, M., Di Pietro, A., Ascierto, P.A.

Get full text

1127P Correlation of BRAF mutation status in circulating tumour DNA (ctDNA) with tumour biopsy and clinical outcomes in COLUMBUS by Robert, C., Flaherty, K.T., Gogas, H.J., Fernandez, A.M. Arance, Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., de Groot, J.W.B., Dutriaux, C., Loquai, C., Harney, A., Kiprilov, E., Pickard, M.D., Cantey-Kiser, J., Dummer, R., Ascierto, P.A.

Get full text

1373TiP - ILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, M.O., Robert, C., Negrier, S., In, G.K., Walker, J., Krajsova, I., Atkinson, V.G., Hansson, J., Kapiteijn, E., Loquai, C., Shaw, H.M., Cheng, T., Mansard, S., Grob, J.J., Guidoboni, M., Mehta, M., Ascierto, P.A., Diab, A.

“…Tilsotolimod (IMO-2125) is a Toll-like receptor (TLR) 9 agonist with potent immunostimulating activity. In an ongoing phase I/II clinical study in patients…”
Get full text

1373TiPILLUMINATE 301: A randomized phase III study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, M O, Robert, C, Negrier, S, In, G K, Walker, J, Krajsova, I, Atkinson, V G, Hansson, J, Kapiteijn, E, Loquai, C, Shaw, H M, Cheng, T, Mansard, S, Grob, J J, Guidoboni, M, Mehta, M, Ascierto, P A, Diab, A

“…Abstract Background Tilsotolimod (IMO-2125) is a Toll-like receptor (TLR) 9 agonist with potent immunostimulating activity. In an ongoing phase I/II clinical…”
Get full text

ILLUMINATE 301: A randomized phase 3 study of tilsotolimod in combination with ipilimumab compared with ipilimumab alone in patients with advanced melanoma following progression on or after anti-PD-1 therapy by Butler, Marcus O., Robert, Caroline, Negrier, Sylvie, In, Gino Kim, Walker, John WT, Krajsova, Ivana, Atkinson, Victoria, Hansson, Johan, Kapiteijn, Ellen, Loquai, Carmen, Shaw, Heather May, Cheng, Tina, Mansard, Sandrine, Grob, Jean Jacques, Guidoboni, Massimo, Mehta, Minal, Ascierto, Paolo Antonio, Diab, Adi

“…Abstract only TPS9599 Background: Tilsotolimod (IMO-2125) is a Toll-like receptor (TLR) 9 agonist with potent immunostimulating activity. In an ongoing Phase…”
Get full text

Combi-V: a Randomised, Open-Label, Phase III Study Comparing the Combination of Dabrafenib (D) and Trametinib (T) with Vemurafenib (V) As First-Line Therapy in Patients (Pts) with Unresectable or Metastatic Braf V600E/K Mutation-Positive Cutaneous Melanoma by Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsova, I., Hauschild, A., Sun, P., Rubin, S.D., Legos, J., Crist, W.A., Little, S.M., Schadendorf, D.

Get full text

LBA4_PRCOMBI-V: A RANDOMISED, OPEN-LABEL, PHASE III STUDY COMPARING THE COMBINATION OF DABRAFENIB (D) AND TRAMETINIB (T) WITH VEMURAFENIB (V) AS FIRST-LINE THERAPY IN PATIENTS (PTS) WITH UNRESECTABLE OR METASTATIC BRAF V600E/K MUTATION-POSITIVE CUTANEOUS MELANOMA by Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroiakovski, D., Lichinitser, M., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsova, I., Hauschild, A., Sun, P., Rubin, S. D., Legos, J., Crist, W. A., Little, S.M., Schadendorf, D.

“…Abstract Aim: BRAFi (D) and MEKi (T) each demonstrated superior progression-free survival (PFS) vs. chemotherapy in pts with BRAF V600E/K mutation-positive…”
Get full text

P39 Giant nodular polypoid melanoma of the neck by Plzakova, Z., Krajsova, I., Sukova, T., Prochazkova, I.

Get full text

Efficacy and safety of aciclovir mucoadhesive buccal tablet in immunocompetent patients with labial herpes (LIP Trial): a double-blind, placebo-controlled, self-initiated trial by Bieber, Thomas, Chosidow, Olivier, Bodsworth, Neil, Tyring, Stephen, Hercogova, Jana, Bloch, Mark, Davis, Matthew, Lewis, Michael, Boutolleau, David, Attali, Pierre

“…Single-day, high-dose systemic antiviral drugs are effective in the treatment of labial herpes (herpes labialis [HL]). Aciclovir Lauriad® mucoadhesive buccal…”
Get more information

Advances in Immunotherapy of Malignant Melanoma by Krajsová, I

“…Development of immunotherapy has dramatically changed poor prognosis of metastatic malignant melanoma (MM). Inhibition of immune checkpoints represents a new…”
Get more information

Three-year estimate of overall survival in COMBI-v, a randomized phase 3 study evaluating first-line dabrafenib (D) + trametinib (T) in patients (pts) with unresectable or metastatic BRAF V600E/K–mutant cutaneous melanoma by Robert, C., Karaszewska, B., Schachter, J., Rutkowski, P., Mackiewicz, A., Stroyakovskiy, D., Dummer, R., Grange, F., Mortier, L., Chiarion-Sileni, V., Drucis, K., Krajsová, I., Hauschild, A., Mookerjee, B., Legos, J.J., Zhang, Y., Lane, S., Schadendorf, D.

Get full text

Données de survie globale de l’étude COLUMBUS, étude de phase III avec encorafénib (ENCO) plus binimétinib (BINI) versus vémurafénib (VEM) ou encorafénib (ENCO) dans le mélanome métastatique BRAF muté by Robert, C., Dummer, R., Ascierto, P.A., Gogas, H.J., Arance, A., Mandala, M., Liszkay, G., Garbe, C., Schadendorf, D., Krajsova, I., Gutzmer, R., Chiarion Sileni, V., Dutriaux, C., de Groot, J.W.B., Yamazaki, N., Loquai, C., Moutouh-de Parseval, L.A., Pickard, M.D., Sandor, V., Flaherty, K.T.

“…Un traitement associant des inhibiteurs de BRAF et de MEK est le traitement de référence des mélanomes avancés porteur d’une mutation BRAFV600. La partie 1 de…”
Get full text

Importance of the Immune System and Immunotherapeutic Options in Malignant Melanoma by Krajsová, I

“…Over the past several years, many important changes in the treatment of metastatic melanoma have occurred. New treatment options have been discovered to…”
Get more information

1041MO 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma by Dummer, R., Flaherty, K.T., Robert, C., Arance, A., de Groot, J.W.B., Garbe, C., Gogas, H.J., Gutzmer, R., Krajsová, I., Liszkay, G., Loquai, C., Mandala, M., Schadendorf, D., Yamazaki, N., Zohren, F., Edwards, M., Ascierto, P.A.

Get full text